DK4140491T5 - Fremgangsmåde til syntetisering af RNA'er med 5'-kappe - Google Patents

Fremgangsmåde til syntetisering af RNA'er med 5'-kappe Download PDF

Info

Publication number
DK4140491T5
DK4140491T5 DK22190426.1T DK22190426T DK4140491T5 DK 4140491 T5 DK4140491 T5 DK 4140491T5 DK 22190426 T DK22190426 T DK 22190426T DK 4140491 T5 DK4140491 T5 DK 4140491T5
Authority
DK
Denmark
Prior art keywords
synthesizing
capped rnas
rnas
capped
Prior art date
Application number
DK22190426.1T
Other languages
English (en)
Other versions
DK4140491T3 (da
Inventor
Richard I Hogrefe
Alexandre Lebedev
Anton P Mccaffrey
Dongwon Shin
Original Assignee
Trilink Biotechnologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58387109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4140491(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trilink Biotechnologies Llc filed Critical Trilink Biotechnologies Llc
Application granted granted Critical
Publication of DK4140491T3 publication Critical patent/DK4140491T3/da
Publication of DK4140491T5 publication Critical patent/DK4140491T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK22190426.1T 2015-09-21 2016-09-20 Fremgangsmåde til syntetisering af RNA'er med 5'-kappe DK4140491T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221248P 2015-09-21 2015-09-21
EP21173278.9A EP3906789B1 (en) 2015-09-21 2016-09-20 Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas

Publications (2)

Publication Number Publication Date
DK4140491T3 DK4140491T3 (da) 2023-11-27
DK4140491T5 true DK4140491T5 (da) 2024-07-22

Family

ID=58387109

Family Applications (6)

Application Number Title Priority Date Filing Date
DK24186081.6T DK4424835T3 (da) 2015-09-21 2016-09-20 Sammensætninger og fremgangsmåder til syntesering af 5'-ende RNA'er med kappe
DK21173142.7T DK3954225T5 (da) 2015-09-21 2016-09-20 Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe
DK16849423.5T DK3352584T3 (da) 2015-09-21 2016-09-20 Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe
DK21173278.9T DK3906789T5 (da) 2015-09-21 2016-09-20 Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe
DK22175377.5T DK4104687T5 (da) 2015-09-21 2016-09-20 Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe
DK22190426.1T DK4140491T5 (da) 2015-09-21 2016-09-20 Fremgangsmåde til syntetisering af RNA'er med 5'-kappe

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DK24186081.6T DK4424835T3 (da) 2015-09-21 2016-09-20 Sammensætninger og fremgangsmåder til syntesering af 5'-ende RNA'er med kappe
DK21173142.7T DK3954225T5 (da) 2015-09-21 2016-09-20 Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe
DK16849423.5T DK3352584T3 (da) 2015-09-21 2016-09-20 Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe
DK21173278.9T DK3906789T5 (da) 2015-09-21 2016-09-20 Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe
DK22175377.5T DK4104687T5 (da) 2015-09-21 2016-09-20 Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe

Country Status (21)

Country Link
US (9) US10913768B2 (da)
EP (9) EP3906789B1 (da)
JP (4) JP6814997B2 (da)
KR (3) KR102670937B1 (da)
CN (8) CN116751827B (da)
AU (5) AU2016328645C1 (da)
CA (2) CA2999274C (da)
CY (1) CY1124306T1 (da)
DK (6) DK4424835T3 (da)
ES (5) ES2964690T3 (da)
FI (5) FI4424835T3 (da)
HK (1) HK1255236A1 (da)
HR (1) HRP20211091T1 (da)
HU (5) HUE055458T2 (da)
LT (6) LT3954225T (da)
PL (5) PL3906789T3 (da)
PT (6) PT4424835T (da)
RS (1) RS62129B1 (da)
SI (5) SI4104687T1 (da)
SM (1) SMT202100396T1 (da)
WO (1) WO2017053297A1 (da)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
ES2964690T3 (es) * 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
JP2019500899A (ja) 2015-11-23 2019-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
JP2020508056A (ja) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ 遺伝子編集のための組成物および方法
AU2018240515B2 (en) 2017-03-24 2024-07-25 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
CN111417724A (zh) 2017-06-30 2020-07-14 科德克希思公司 T7 rna聚合酶变体
US10793841B2 (en) * 2017-06-30 2020-10-06 Codexis, Inc. T7 RNA polymerase variants
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
EP3688161A1 (en) 2017-09-29 2020-08-05 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating attr amyloidosis
AR113154A1 (es) 2017-09-29 2020-01-29 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para edición del genoma
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
JP7445657B2 (ja) 2018-12-06 2024-03-07 アークトゥラス・セラピューティクス・インコーポレイテッド オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
AU2020220357B2 (en) 2019-02-11 2025-06-26 Ethris Gmbh mRNA purification by tangential flow filtration
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
AU2020248337A1 (en) 2019-03-28 2021-11-04 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
EP3946598A1 (en) 2019-03-28 2022-02-09 Intellia Therapeutics, Inc. Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
BR112021019224A2 (pt) 2019-03-28 2021-11-30 Intellia Therapeutics Inc Polinucleotídeos, composições e métodos para expressão de polipeptídeo
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control
US20220362360A1 (en) * 2019-04-26 2022-11-17 Etherna Immunotherapies Nv Mrna formulation
CN114126668A (zh) * 2019-05-24 2022-03-01 超基因制药股份有限公司 用于血色素沉积症治疗的组合物和方法
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
EP4003508A1 (en) 2019-07-31 2022-06-01 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
EP4013880A1 (en) 2019-08-14 2022-06-22 CureVac AG Rna combinations and compositions with decreased immunostimulatory properties
JP2022546417A (ja) * 2019-08-29 2022-11-04 チューリッヒ大学 最小ｍＲＮＡおよびその使用
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
MX2022009460A (es) 2020-02-04 2022-12-16 Curevac Ag Vacuna contra el coronavirus.
PL248416B1 (pl) * 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432884A1 (pl) 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
EP4112630B1 (en) 2020-02-28 2024-10-16 Japan Science and Technology Agency Method for producing capped rna
CN113151312B (zh) * 2020-03-02 2022-12-09 中国科学院微生物研究所 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用
JP7832114B2 (ja) 2020-03-03 2026-03-17 アークトゥラス・セラピューティクス・インコーポレイテッド オルニチントランスカルバミラーゼ欠損症の治療のための組成物及び方法
WO2021183563A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
WO2021198157A1 (en) 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
WO2021216776A2 (en) 2020-04-21 2021-10-28 Gritstone Bio, Inc. Capping compounds, compositions and methods of use thereof
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
US12070509B2 (en) 2020-05-01 2024-08-27 Arcturus Therapeutics, Inc. Nucleic acids and methods of treatment for cystic fibrosis
CN115916978A (zh) 2020-05-19 2023-04-04 哈德森医学研究所 寡核苷酸
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
KR20230034333A (ko) * 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN113416762A (zh) * 2020-08-20 2021-09-21 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
US20240246056A1 (en) 2020-09-01 2024-07-25 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
CN116368226A (zh) 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
KR102366490B1 (ko) 2020-10-20 2022-02-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
JP7641487B2 (ja) 2020-11-27 2025-03-07 キュアバック マニュファクチャリング ゲーエムベーハー キャピラリーポリメラーゼ連鎖反応によってｄｎａ産物を調製するためのデバイス
AU2021395736A1 (en) 2020-12-09 2023-07-27 BioNTech SE Rna manufacturing
CR20230305A (es) 2020-12-11 2023-11-10 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US20240316090A1 (en) 2020-12-28 2024-09-26 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
WO2022175815A1 (en) 2021-02-19 2022-08-25 Pfizer Inc. Methods of protecting rna
US20240181037A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
KR20220140140A (ko) 2021-04-09 2022-10-18 한미정밀화학주식회사 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US20240321387A1 (en) 2021-05-04 2024-09-26 BioNTech SE Immunogen selection
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
KR20240038705A (ko) 2021-06-22 2024-03-25 인텔리아 테라퓨틱스, 인크. 간 유전자의 생체 내 편집 방법
CN117858885A (zh) 2021-07-05 2024-04-09 国立研究开发法人科学技术振兴机构 核苷酸类的纯化方法和核苷酸类的纯化装置以及疏水性试剂和疏水性底物
EP4116313A1 (en) 2021-07-07 2023-01-11 Westfälische Wilhelms-Universität Münster Cap analog for the 5'-end of eukaryotic messenger rnas
WO2023006920A1 (en) 2021-07-29 2023-02-02 BioNTech SE Compositions and methods for treatment of melanoma
CA3171750A1 (en) 2021-07-30 2023-02-02 Tim SONNTAG Mrnas for treatment or prophylaxis of liver diseases
EP4377326A1 (en) 2021-07-30 2024-06-05 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
JP2024534120A (ja) 2021-08-24 2024-09-18 ビオンテック・ソシエタス・エウロパエア インビトロ転写技術
CN118978560A (zh) 2021-08-27 2024-11-19 上海兆维科技发展有限公司 一种加帽类似物及其应用
AU2022338639A1 (en) 2021-08-31 2024-02-08 Hanmi Fine Chemical Co., Ltd. Mrna cap analogue and use thereof
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
CN113957108B (zh) * 2021-09-09 2025-01-10 上海兆维科技发展有限公司 一种加帽rna的合成方法以及加帽rna转录反应液
WO2023067125A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
JP2024540979A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
WO2023067126A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
JP2024543247A (ja) 2021-10-22 2024-11-20 ビオンテック・ソシエタス・エウロパエア オリゴ糖化合物及び複合体
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4402149A1 (en) 2021-10-22 2024-07-24 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
EP4426822A2 (en) 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20230083197A (ko) 2021-12-01 2023-06-09 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
WO2023115495A1 (zh) * 2021-12-23 2023-06-29 北京毅新博创生物科技有限公司 质谱法检测mRNA加帽效率的方法
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
KR20230123318A (ko) 2022-02-16 2023-08-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
GB2615784A (en) 2022-02-18 2023-08-23 Phion Therapeutics Ltd mRNA vaccine
JP7642260B2 (ja) 2022-02-28 2025-03-10 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 Ｒｎａキャッピング用化合物及びその使用
CN115260264B (zh) 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
JP2025507894A (ja) * 2022-03-01 2025-03-21 ヴァーヴ・セラピューティクス，インコーポレーテッド Ｒｎａをキャッピングするための組成物及び方法
CN119053705A (zh) 2022-03-21 2024-11-29 克里斯珀医疗股份公司 用于治疗脂蛋白相关疾病的方法和组合物
AU2023241456A1 (en) * 2022-03-31 2024-09-05 Hanmi Fine Chemical Co., Ltd. Mrna cap analog and uses thereof
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物
GB2618818A (en) 2022-05-18 2023-11-22 Phion Therapeutics Ltd Vaccine
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US20250375534A1 (en) 2022-05-30 2025-12-11 BioNTech SE Complexes for delivery of nucleic acids
WO2023235422A2 (en) * 2022-05-31 2023-12-07 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2023235362A1 (en) * 2022-05-31 2023-12-07 Nutcracker Therapeutics, Inc. Rna cap analogs and methods of use
CN119384498A (zh) 2022-06-16 2025-01-28 因特利亚治疗公司 用于对细胞进行遗传修饰的方法和组合物
WO2023246860A1 (zh) * 2022-06-22 2023-12-28 江苏申基生物科技有限公司 一种起始加帽寡核苷酸引物及其制备方法和应用
CN114853836B (zh) * 2022-06-24 2024-05-14 江苏申基生物科技有限公司 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用
CN115057903B (zh) * 2022-06-22 2024-03-29 江苏申基生物科技有限公司 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用
CN115109110B (zh) * 2022-06-22 2024-07-12 江苏申基生物科技有限公司 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN114941018B (zh) * 2022-06-28 2023-09-22 翌圣生物科技(上海)股份有限公司 cap1帽类似物的合成方法
KR20240010238A (ko) 2022-07-15 2024-01-23 한미정밀화학주식회사 캡 유사체 및 이의 용도
CN117430652A (zh) * 2022-07-22 2024-01-23 广州市恒诺康医药科技有限公司 用于rna加帽的环状取代化合物及其应用
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA
CN115925773A (zh) * 2022-08-23 2023-04-07 合肥华纳生物医药科技有限公司 一种新型信使核糖核酸帽类似物
CN120129688A (zh) * 2022-08-26 2025-06-10 垂林克生物技术有限公司 用于制备高度纯化的5′-加帽寡核苷酸的高效方法
WO2024051696A1 (zh) * 2022-09-05 2024-03-14 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4583889A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025532191A (ja) 2022-09-26 2025-09-29 ビオンテック・ソシエタス・エウロパエア 核酸複合体及びその使用
CN119947747A (zh) 2022-09-26 2025-05-06 葛兰素史克生物有限公司 流感病毒疫苗
IL319652A (en) 2022-10-04 2025-05-01 BioNTech SE RNA structures and their uses
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
CN120129702A (zh) 2022-10-06 2025-06-10 生物技术公司 靶向密蛋白-18.2的rna组合物
EP4605010A1 (en) 2022-10-21 2025-08-27 BioNTech SE Nucleic acid complexes and uses thereof
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
CN116143855B (zh) * 2022-11-08 2023-11-28 江苏申基生物科技有限公司 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用
WO2024138115A1 (en) 2022-12-23 2024-06-27 Intellia Theraperutics, Inc. Systems and methods for genomic editing
EP4397669A1 (en) 2023-01-06 2024-07-10 Westfälische Wilhelms-Universität Münster Photocaged cap analogs for the 5'-end of rnas
TW202444408A (zh) 2023-01-20 2024-11-16 瑞典商阿斯特捷利康公司 疫苗
IL322194A (en) 2023-01-20 2025-09-01 Astrazeneca Ab Nucleic acid molecules
WO2024160895A1 (en) 2023-01-31 2024-08-08 CureVac SE Cap analogs with 5'-terminal acyclic guanosine derivative
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024185734A1 (ja) 2023-03-03 2024-09-12 株式会社ナティアス ポリリン酸化ヌクレオシド、ポリリン酸化ヌクレオシドの合成に用いられるリン酸部活性化ヌクレオチド及びその合成方法、ならびにリン酸部活性化ヌクレオチドを用いたポリリン酸化ヌクレオシドの合成方法
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
CN116356002A (zh) * 2023-03-28 2023-06-30 四川康德赛医疗科技有限公司 一种rna加帽效率的定量方法、试剂盒及其应用
WO2024206565A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems
TW202444906A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 用於靶向pcsk9之組合物及方法
CN118726510A (zh) * 2023-03-31 2024-10-01 苏州近岸蛋白质科技股份有限公司 一管法酶促合成加帽mRNA的方法
CN118772219B (zh) * 2023-04-04 2025-12-02 深圳瑞吉生物科技有限公司 一种用于核酸的5’端加帽的含卤化合物及其应用
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
EP4701658A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
EP4713483A1 (en) 2023-05-16 2026-03-25 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
AU2024278682A1 (en) 2023-05-26 2025-11-27 CureVac SE Cancer antigens
EP4731655A1 (en) 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies
WO2025006851A1 (en) 2023-06-29 2025-01-02 Nutcracker Therapeutics, Inc. Ethyl modified rna caps and methods of use
AU2024301706A1 (en) 2023-07-21 2026-02-05 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025027060A1 (en) 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
IL326176A (en) 2023-08-01 2026-03-01 BioNTech SE Ionizable Thiolipids and Their Uses
WO2025036992A1 (en) 2023-08-16 2025-02-20 CureVac SE Rna conjugates
CN117362360A (zh) * 2023-08-21 2024-01-09 星锐医药(苏州)有限公司 一种帽类似物的制备方法
IL326531A (en) * 2023-09-06 2026-04-01 Trilink Biotechnologies Llc Cap analogues and methods of their use
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025071359A1 (ko) 2023-09-27 2025-04-03 한미정밀화학 주식회사 mRNA 캡 유사체 및 이의 용도
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
TW202540417A (zh) 2023-11-10 2025-10-16 美商英特利亞醫療公司 用於基因體編輯之組合物、方法及系統
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025129157A1 (en) 2023-12-15 2025-06-19 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of canavan disease
WO2025137301A1 (en) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Methods for rapid engineering of cells
TW202525287A (zh) 2023-12-21 2025-07-01 德商拜恩技術運輸科技有限責任公司 可離子化脂質
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025147660A2 (en) 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
CN117534719B (zh) 2024-01-09 2024-05-14 北京悦康科创医药科技股份有限公司 一种c6'取代锁核酸修饰加帽类似物及其应用
WO2025181704A2 (en) 2024-02-27 2025-09-04 Crispr Therapeutics Ag Rt editing compositions and methods
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
US12492420B2 (en) 2024-03-29 2025-12-09 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
EP4650358A3 (en) * 2024-04-26 2026-01-14 Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. Ribose-modified cap analog and use thereof
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
WO2025264662A1 (en) 2024-06-18 2025-12-26 BioNTech SE Compositions and methods for treatment of melanoma
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
WO2026010855A1 (en) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
WO2026033380A1 (en) 2024-08-05 2026-02-12 BioNTech SE Process for preparing oligosaccharide complexes
WO2026078020A2 (en) 2024-10-07 2026-04-16 Explorna Therapeutics Sp. Z O. O. Efficient in vitro transcription of artificial mrna with highly modified 5' ends
EP4722375A1 (en) 2024-10-07 2026-04-08 ExploRNA Therapeutics Sp. z o. o. Efficient in vitro transcription of artificial mrna with highly modified 5' ends
CN120608113B (zh) * 2024-11-29 2026-04-10 上海蓝鹊生物医药有限公司 一种合成Cap2结构5'-加帽RNA的组合和方法
CN119306779A (zh) * 2024-12-13 2025-01-14 上海科泽永欣生物科技有限公司 一种含r构型的起始加帽寡核苷酸引物及其合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1997A (en) 1841-03-03 Improvement in the mode of rendering fabrics water-proof
EP0081099A3 (en) * 1981-12-04 1983-08-10 Sloan-Kettering Institute For Cancer Research Capped oligonucleotide anti-viral agents
DE3148702C2 (de) * 1981-12-09 1985-05-15 Dieter Gräßlin Feinwerktechnik, 7742 St Georgen Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte
US5837852A (en) 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
AU2998800A (en) 1999-03-24 2000-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The N-acylphosphoramidites and their use in oligonucleotide synthesis
US7074596B2 (en) * 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7629325B2 (en) * 2004-10-11 2009-12-08 Technion Research & Development Foundation Ltd. Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy
EP1819365B1 (en) 2004-12-09 2014-07-02 Alnylam Pharmaceuticals Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
AU2007268075C1 (en) 2006-06-01 2013-03-07 Trilink Biotechnologies Chemically modified oligonucleotide primers for nucleic acid amplification
EP2049665A2 (en) * 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
US20080248469A1 (en) 2006-08-16 2008-10-09 Applera Corporation Methods for Identifying Nucleotides of Interest in Target Polynucleotides
WO2008157688A2 (en) 2007-06-19 2008-12-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US9067964B2 (en) 2008-12-18 2015-06-30 Oligomer Sciences Ab Complex and method for enhancing nuclear delivery
US8557972B2 (en) 2009-12-21 2013-10-15 University Of Washington Through Its Center For Commercialization Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA
WO2011157617A1 (en) 2010-06-17 2011-12-22 Febit Holding Gmbh Complex set of mirna libraries
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
DK2971098T3 (da) 2013-03-14 2019-02-18 Translate Bio Inc Kvantitativ bedømmelse for kappe-effektivitet af messenger rna
JP6148592B2 (ja) 2013-10-15 2017-06-14 ヤマハ発動機株式会社 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両
EP3233880A1 (en) 2014-12-16 2017-10-25 Novartis AG End capped nucleic acid molecules
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
PL248416B1 (pl) 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432884A1 (pl) 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
KR20230034333A (ko) 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
KR102366490B1 (ko) 2020-10-20 2022-02-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드

Also Published As

Publication number Publication date
PT4140491T (pt) 2023-12-05
PT3352584T (pt) 2021-07-13
AU2016328645C1 (en) 2021-10-28
FI4104687T3 (fi) 2024-03-01
CA2999274A1 (en) 2017-03-30
EP4276189A3 (en) 2024-01-17
EP4717779A2 (en) 2026-04-01
DK3906789T5 (da) 2024-08-05
LT3352584T (lt) 2021-08-10
LT4424835T (lt) 2026-03-10
LT3954225T (lt) 2024-02-12
PL3906789T3 (pl) 2024-05-20
US11578095B2 (en) 2023-02-14
JP2021048864A (ja) 2021-04-01
EP4104687B1 (en) 2024-01-31
US20220289786A1 (en) 2022-09-15
CN121064267A (zh) 2025-12-05
AU2025203425A1 (en) 2025-05-29
EP3352584B1 (en) 2021-05-12
PT4424835T (pt) 2026-02-25
EP4276189B1 (en) 2026-04-01
DK4424835T3 (da) 2026-03-23
US10519189B2 (en) 2019-12-31
US11878991B2 (en) 2024-01-23
DK3352584T3 (da) 2021-07-12
US20190270766A1 (en) 2019-09-05
FI4140491T3 (fi) 2023-11-20
CN116751827B (zh) 2024-01-30
EP3906789B1 (en) 2023-11-22
US20240158433A1 (en) 2024-05-16
AU2021206780C1 (en) 2024-01-04
HRP20211091T1 (hr) 2021-10-15
EP4140491B1 (en) 2023-09-13
PL3352584T3 (pl) 2021-11-08
SI3906789T1 (sl) 2024-03-29
US10913768B2 (en) 2021-02-09
LT3906789T (lt) 2024-02-12
HUE065331T2 (hu) 2024-05-28
ES2968335T3 (es) 2024-05-09
KR102670937B1 (ko) 2024-05-31
CN121085982A (zh) 2025-12-09
CN120842296A (zh) 2025-10-28
ES2968391T3 (es) 2024-05-09
FI4424835T3 (fi) 2026-03-24
CN116590285A (zh) 2023-08-15
US12103944B2 (en) 2024-10-01
FI3906789T3 (fi) 2024-01-11
PL4140491T3 (pl) 2024-02-26
KR20230026535A (ko) 2023-02-24
US20180273576A1 (en) 2018-09-27
SI4140491T1 (sl) 2024-01-31
WO2017053297A1 (en) 2017-03-30
CY1124306T1 (el) 2022-07-22
EP4424835A2 (en) 2024-09-04
KR20240095306A (ko) 2024-06-25
ES2964690T3 (es) 2024-04-09
DK4104687T3 (da) 2024-03-04
SI3352584T1 (sl) 2021-09-30
DK3954225T3 (da) 2024-01-02
HUE064227T2 (hu) 2024-02-28
EP4424835B1 (en) 2026-01-21
ES2879686T3 (es) 2021-11-22
EP3352584A4 (en) 2019-03-27
EP4140491A1 (en) 2023-03-01
JP6814997B2 (ja) 2021-01-20
AU2023229522B2 (en) 2025-02-20
RS62129B1 (sr) 2021-08-31
DK3954225T5 (da) 2024-08-05
PL3954225T3 (pl) 2024-05-20
US20250171489A1 (en) 2025-05-29
EP3954225B1 (en) 2023-11-22
AU2023201915B2 (en) 2024-07-25
AU2023229522A1 (en) 2023-09-28
LT4140491T (lt) 2023-11-10
US20240140982A1 (en) 2024-05-02
SI4104687T1 (sl) 2024-03-29
US20190144490A1 (en) 2019-05-16
JP2022109973A (ja) 2022-07-28
CA3218662A1 (en) 2017-03-30
HK1255236A1 (zh) 2019-08-09
AU2016328645B2 (en) 2021-05-13
AU2021206780B2 (en) 2023-04-06
DK4140491T3 (da) 2023-11-27
PT3954225T (pt) 2024-01-02
KR20180050409A (ko) 2018-05-14
DK3906789T3 (da) 2024-01-08
US20210371452A1 (en) 2021-12-02
CA2999274C (en) 2023-12-19
CN108366604A (zh) 2018-08-03
FI3954225T3 (fi) 2023-12-28
PT3906789T (pt) 2023-12-18
SI3954225T1 (sl) 2024-03-29
JP7082174B2 (ja) 2022-06-07
EP4424835A3 (en) 2024-10-23
HUE065203T2 (hu) 2024-05-28
HUE055458T2 (hu) 2021-11-29
US10494399B2 (en) 2019-12-03
US12258369B2 (en) 2025-03-25
ES2972098T3 (es) 2024-06-11
CN113584020A (zh) 2021-11-02
EP4276189A2 (en) 2023-11-15
US20210261597A1 (en) 2021-08-26
LT4104687T (lt) 2024-02-26
EP3954225A1 (en) 2022-02-16
PL4104687T3 (pl) 2024-05-27
EP4104687A1 (en) 2022-12-21
HUE065704T2 (hu) 2024-06-28
JP2018527015A (ja) 2018-09-20
JP2024150459A (ja) 2024-10-23
PT4104687T (pt) 2024-02-27
AU2016328645A1 (en) 2018-04-19
JP7594563B2 (ja) 2024-12-04
SMT202100396T1 (it) 2021-09-14
CN117025590A (zh) 2023-11-10
AU2021206780A1 (en) 2021-08-12
KR102500198B1 (ko) 2023-02-16
CN116751827A (zh) 2023-09-15
AU2023201915A1 (en) 2023-05-04
EP3954224A1 (en) 2022-02-16
EP3352584A1 (en) 2018-08-01
EP3906789A1 (en) 2021-11-10
DK4104687T5 (da) 2024-07-22
US11414453B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
DK4140491T5 (da) Fremgangsmåde til syntetisering af RNA'er med 5'-kappe
IL284651B (en) 3' utr sequences for stabilization of rna
DK3585892T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3585891T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3294885T3 (da) Fremgangsmåde til at fremstille rna
DK3134506T4 (da) Fremgangsmåder til oprensning af messenger rna
DK3445850T3 (da) Fremgangsmåder til tilvejebringelse af enkeltstrenget rna
DK3319622T3 (da) Fremgangsmåde til fremstilling af rna-molekylesammensætninger
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3728585T3 (da) Hidtil ukendte fremgangsmåder til fremstilling af oligonukleotider
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3607068T3 (da) RNA-interferensmedieret inhibering af TMPRSS6
EP3323147A4 (en) METHOD FOR SELECTIVE EPITAXIA
DK3374333T3 (da) Fremgangsmåde til fremstilling af urea-gødningsmiddel
DK3191498T3 (da) Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3347481T3 (da) Fremgangsmåde til oprensning af biomassehydrolysat
DK3386947T3 (da) Fremgangsmåde til fremstilling af n-retinoylaminoalkansulfonsyre
DK3733865T3 (da) Fremgangsmåde til opnåelse af encellet mrna-sekvens
DK3328816T3 (da) Fremgangsmåde til genvinding af fosfor
DK3356540T3 (da) Fremgangsmåde til fremstilling af l-methionin
DK3356541T3 (da) Fremgangsmåde til fremstilling af l-methionin
DK3652187T3 (da) Forbedret fremgangsmåde til fremstilling af imetelstat
DK3381914T3 (da) Fremgangsmåde til oprensning af benzopyranderivat, krystallinsk form deraf og fremgangsmåde til fremstilling af den krystallinske form
DK3371197T3 (da) Fremgangsmåde til selektiv syntese af trialkoxysilaner
DK3294725T3 (da) Fremgangsmåde til fremstilling af 4-aminopyridaziner